Loading…
BLCO
Bausch & Lomb Corp
NYSE· Healthcare· Medical Instruments & Supplies· CUSIP 071705107
$17.43+1.46%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Bausch & Lomb Corp (BLCO) is listed on NYSE and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Vaughan, Canada and has 13,000 employees. The company is worth $6.23B. Revenue was $5.1B in fiscal 2025, up 6.5% from the year before. It reported a net loss of $360M. The share price is 7.9% below its 52-week high of $18.92. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Carl Icahn (Icahn Enterprises), at $57.96M. In that quarter, 2 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $6.23B
- P/E
- —
- Forward P/E
- 15.7x
- P/B
- 1.0x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$0.50
- ROE
- -2.52%
- Profit margin
- -3.21%
- Revenue growth
- +9.10%
- Beta
- 0.56
- 52-week high
- $18.92
- 52-week low
- $14.44
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Carl IcahnHeldIcahn Enterprises · Q2 2026$57.96M3.5M shares · 0.7% of portfolio
Howard MarksHeldOaktree Capital Management · Q2 2026$56.98M3.44M shares · 1.5% of portfolio
Ken GriffinAddedCitadel Advisors · Q2 2026$16.36M987.73K shares · 0.0% of portfolio- Israel EnglanderReducedMillennium Management · Q2 2026$2.93M176.74K shares · 0.0% of portfolio
- Steve CohenReducedPoint72 Asset Management · Q2 2026$2.91M175.82K shares · 0.0% of portfolio
- Dan LoebNew positionThird Point · Q2 2026$1.41M85K shares · 0.0% of portfolio
- Two SigmaHeldTwo Sigma Investments · Q2 2026$847.87K51.2K shares · 0.0% of portfolio
Price over time
▼ -3.1% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $17.08 | $18.06 | $17.06 | $15.51 | |
| P/E | — | — | — | — | 775.5x |
| P/S | 1.4x | 1.2x | 1.3x | 1.4x | 1.4x |
| P/B | 0.9x | 0.9x | 1.0x | 0.9x | 0.8x |
| EPS | -$1.02 | -$0.90 | -$0.74 | $0.02 | |
| Profit margin | -6.44% | -7.06% | -6.62% | -6.27% | 0.16% |
| ROE | -4.35% | -5.58% | -4.90% | -3.80% | 0.09% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
$8.03
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Operating $8.03÷ 1 =$8.03
$8.03
1 methods answered, across 1 families.
$6.02
Room for errors in the reported numbers.
$17.43
-53.9% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RYTMRhythm Pharmaceuticals Inc | $90.90 | — | 60.8x | 0.00% | -117.05% | $6.26B |
| KNSAKiniksa Pharmaceuticals International, plc | $80.79 | 80.8x | 9.6x | 0.00% | 14.04% | $6.3B |
| LGNDLigand Pharmaceuticals Inc | $307.82 | 32.4x | 6.3x | 0.00% | 21.96% | $6.14B |
| BLTEBelite Bio Inc | $150.27 | — | 7.8x | 0.00% | -22.10% | $6.05B |
| IOVAIovance Biotherapeutics Inc | $14.14 | — | 8.7x | 0.00% | -40.36% | $6.41B |
| IMVTImmunovant, Inc. | $29.10 | — | 8.2x | 0.00% | -80.10% | $6.01B |
About the company
- 13,000
- Vaughan, Canada